Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)

Completed · Phase 3 · Has a placebo group

Conditions studied: Attention Deficit Hyperactivity Disorder (ADHD)

In brief

The study is designed to evaluate the efficacy and safety of each dose of SHP465 (12.5 and 37.5 mg) given to participants daily in the morning compared to placebo in the treatment of adults aged 18 to 55 years diagnosed with ADHD.

Key facts

Study ID: NCT02604407
Run by: Shire
People needed: 275
Starts: 2015-11-19
Expected to finish: 2016-03-24
Last updated by the study team: 2021-06-03

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Subject must be 18-55 years of age
Subject is able to provide written, personally signed and dated informed consent.
Subject is willing and able to comply with all of the testing and requirements defined in the protocol
Subject, who is a female, must not be pregnant.
Subject must have a satisfactory medical assessment with no clinically significant or relevant abnormalities.
Subject has a primary diagnosis of ADHD.
Subject has an adult ADHD-RS with prompts total score ≥28 at the baseline visit.
Subject must have a minimum level of intellectual functioning, as determined by the investigator.
Subject is able to swallow a capsule.
Subject is currently not on ADHD therapy or is not completely satisfied with any aspect of their current ADHD therapy.

You may not qualify if…

Subject has a current, comorbid psychiatric diagnosis with significant symptoms.
Subject is considered a suicide risk in the opinion of the investigator
Subject has a body mass index (BMI) of <18.5 kg/m2 at the screening visit.
Subject has a BMI ≥40 kg/m2 at the screening visit.
Subject has a concurrent chronic or acute illness, disability, or other condition.
Subject has a history of seizure, a chronic or current tic disorder, or a current diagnosis of Tourette's disorder.
Subject has a history of moderate to severe hypertension.
Subject has a known history of symptomatic cardiovascular disease
Subject has a known family history of sudden cardiac death or ventricular arrhythmia.
Subject has any clinically significant ECG or clinically significant laboratory abnormality at the screening visit.
Subject has current abnormal thyroid function
Subject has a documented allergy, hypersensitivity, or intolerance to amphetamine or to any excipients in the investigational product.
Subject has failed to respond, to an adequate course(s) of amphetamine therapy.
Subject has a history of suspected substance abuse or dependence disorder.
Subject has a positive urine drug result at the screening visit (with the exception of subject's current stimulant therapy, if any) or Subject has taken another investigational product or has taken part in a clinical study within 30 days prior to the screening visit.
Subject has previously completed, has discontinued, or was withdrawn from this study.
Subject is taking any medication that is excluded or has not been appropriately washed out according to the protocol requirements.
Subject is required to take or anticipates the need to take medications that have CNS effects or affect performance.
Subject is female and is pregnant or lactating.

Where it is running

Pharmacology Research Institute — Encino, California, United States
Pharmacology Research Institute (Pri) — Los Alamitos, California, United States
Pharmacology Research Institute (Pri) — Newport Beach, California, United States
Nrc Research Institute — Orange, California, United States
Elite Clinical Trials — Wildomar, California, United States
McB Clinical Research — Colorado Springs, Colorado, United States
Florida Clinical Research Center Llc — Bradenton, Florida, United States
Gulfcoast Clinical Research Center — Fort Myers, Florida, United States
Sarkis Clinical Trials — Gainesville, Florida, United States
Clinical Neuroscience Solutions, Inc — Jacksonville, Florida, United States
Florida Clinical Research Center, Llc — Maitland, Florida, United States
Qps Mra, Llc — Miami, Florida, United States
Medical Research Group of Central Florida — Orange City, Florida, United States
Clinical Neuroscience Solutions, Inc — Orlando, Florida, United States
Northwest Behavioral Research Center — Marietta, Georgia, United States
Capstone Clinical — Libertyville, Illinois, United States
Baber Research Group, Inc — Naperville, Illinois, United States
Psychiatric Associates — Overland Park, Kansas, United States
Louisiana Research Associates, Inc. — New Orleans, Louisiana, United States
Rochester Center For Behavioral Medicine — Rochester Hills, Michigan, United States
Clinical Neurophysiology Services — Sterling Heights, Michigan, United States
Psychiatric Care and Research Center — O'Fallon, Missouri, United States
Midwest Research Group — Saint Charles, Missouri, United States
Premier Psychiatric Research Institutute — Lincoln, Nebraska, United States
Center For Psychiatry and Behavioral Medicine, Inc — Las Vegas, Nevada, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.